PrairieGold Venture Partners

Chronix Biomedical, Inc. is a molecular diagnostics company that specializes in developing laboratory-developed tests, specifically blood tests known as liquid biopsies for cancer and organ transplants. Founded in 1997 and headquartered in San Jose, California, Chronix focuses on therapy monitoring for patients undergoing chemotherapy or immunotherapy, as well as relapse monitoring post-tumor resection. Among its notable products are the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, which quantifies transplant-specific DNA in plasma to detect organ rejection early. The company employs proprietary technology to analyze circulating nucleic acids in the blood, enabling healthcare professionals to monitor various chronic diseases and conditions effectively. Chronix also operates research facilities in Brookings, South Dakota, and Göttingen, Germany, and aims to collaborate with partners to further develop its innovative DNA-based assays.

Chronix Biomedical, Inc. is a molecular diagnostics company that specializes in developing laboratory-developed tests, specifically blood tests known as liquid biopsies for cancer and organ transplants. Founded in 1997 and headquartered in San Jose, California, Chronix focuses on therapy monitoring for patients undergoing chemotherapy or immunotherapy, as well as relapse monitoring post-tumor resection. Among its notable products are the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, which quantifies transplant-specific DNA in plasma to detect organ rejection early. The company employs proprietary technology to analyze circulating nucleic acids in the blood, enabling healthcare professionals to monitor various chronic diseases and conditions effectively. Chronix also operates research facilities in Brookings, South Dakota, and Göttingen, Germany, and aims to collaborate with partners to further develop its innovative DNA-based assays.